Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

I'm in London, and I just paid for this damn fat drug I take. I said, it's not working. They said, he said, I just paid $88 ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...

A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may ...

Key health updates involve Brazil's bird flu trade restrictions, Nestle USA's removal of synthetic food colors, Walgreens ...